Ensemble Discovery Announces Additions to its Scientific Advisory Board Adds four distinguished scientists to its world-class SAB
CAMBRIDGE, MA (November 7, 2007) -- Ensemble Discovery Corporation, a biotechnology company developing novel classes of therapeutics and diagnostics using its proprietary DNA Programmed Chemistry™ (DPC™) platform, today announced the appointment of Francis Barany, Ph.D., Simon Campbell CBE, FMedSci, FRS, Gerard Evan, Ph.D., FRS, and Mark Murcko, Ph.D. to its Scientific Advisory Board.
“We are extremely pleased to have recruited such an outstanding group of academic and industry scientists to the Ensemble SAB,” said Michael D. Taylor, CEO of Ensemble. “From a strategic point of view, this group provides us with a strong scientific perspective, both for our current programs as well as insight for future programs utilizing our proprietary DPC platform.”
These new members join a world class SAB led by David Liu, Ph.D., founder of Ensemble Discovery, Professor of Chemistry and Chemical Biology at Harvard University, and Howard Hughes Medical Institute Investigator.
Dr. Barany currently holds the rank of Full Professor in the Department of Microbiology and Program of Biochemistry and Structural Biology at Weill Cornell Medical College. He is also a member of the joint Cornell/Sloan Kettering Institute Molecular Biology Program. Previously he held an adjunct appointment at The Rockefeller University in the Department of Chemistry, Biochemistry, and Structural Biology, as well as an appointment as Director of Mutation Research at the Strang Cancer Prevention Center. Dr. Barany is best known for developing the ligase chain reaction (LCR) and ligase detection reaction (LDR) and Universal DNA arrays for detection of genetic diseases and cancer-associated mutations. In 2004 he was honored as Research leader in Medical Diagnostics in the Scientific American 50 award.
Dr. Campbell has more than 30 years of experience in the pharmaceutical industry, most recently as Senior Vice President for Worldwide Discovery and Medicinals R&D Europe at Pfizer. He has co-authored over 110 publications and patents, and was a key member of the research teams that discovered CarduraTM, NorvascTM, and ViagraTM. Dr Campbell is a Past President of the Royal Society of Chemistry, he was elected Fellow of the Royal Society in 1999 and appointed CBE by the Queen in 2006 for Services to Science.
Dr. Evan is a Gerson and Barbara Bass Bakar Distinguished Professor of Cancer Biology at the University of California, San Francisco. He is also Co-leader of the Cell Cycling and Signaling Program at the UCSF Comprehensive Cancer Center, which he helped create in 1999. Dr. Evan
began his career at the Ludwig Institute for Cancer Research in Cambridge, UK, followed by the Imperial Cancer Research Fund Laboratory in London where he uncovered the link between Myc gene and apoptosis.
Dr. Murcko is Vice President, Chief Technology Officer and Chair of the Scientific Advisory Board of Vertex Pharmaceuticals, responsible for the strategic evaluation, identification, and integration of new technologies into worldwide R&D. He is a co-inventor of several compounds in Vertex's clinical pipeline. Notable among these are Vertex's first two marketed drugs, the HIV protease inhibitors Agenerase® and Lexiva®, as well as the anti-inflammatory compounds Pralnacasan® and VX-765. In addition, he is a co-inventor on more than 30 issued patents and has authored or co-authored more than 75 scientific articles.
About Ensemble Discovery
Based in Cambridge, MA, Ensemble Discovery Corporation is harnessing a fundamentally new approach to controlling chemical reactivity to develop novel classes of therapeutics and diagnostics. Ensemble Discovery is deploying DNA-Programmed Chemistry (DPC), which is based on the groundbreaking work of Professor David Liu of Harvard University and Howard Hughes Medical Institute. In its drug discovery programs, Ensemble uses DPC to generate Programmed Macrocycles as drug candidates for challenging pharmaceutical targets. In its diagnostic programs, Ensemble uses DPC to control the generation of detection signals in response to the presence of specific molecular events underlying human diseases. DPC-based assays are particularly adept at the detection of dimeric molecules such as growth factor receptors on cell surfaces.
For a complete description of Ensemble Discovery Corporation, its product programs and its platform technologies, go to www.ensemblediscovery.com. For More Information, Contact: Laurence Reid Ensemble Discovery Corporation (617) 492-6977 [email protected]
BARONE GIULIO PIZZINI PIOMARTA Soc. Agr. per azioni Via Brescia, 3 25050 TIMOLINE DI CORTE FRANCA BS RAPPORTO DI PROVA n° 10B01996-It-0 CAMPIONE 10B01996 Data Inizio Analisi 04/02/2010 Descrizione dichiarata: VINO IGT SEBINO SAN CARLO 2008 DA AGRICOLTURA BIOLOGICA Lotto/Codice:: 03-2010Richiesta via Internet n° N0003/10 del 02/02/2010 11.41.25. - Data arrivo campi
Ensemble Discovery Announces Additions to its Scientific Advisory Board 
began his career at the Ludwig Institute for Cancer Research in Cambridge, UK, followed by the Imperial Cancer Research Fund Laboratory in London where he uncovered the link between Myc gene and apoptosis.
Dr. Murcko is Vice President, Chief Technology Officer and Chair of the Scientific Advisory Board of Vertex Pharmaceuticals, responsible for the strategic evaluation, identification, and integration of new technologies into worldwide R&D. He is a co-inventor of several compounds in Vertex's clinical pipeline. Notable among these are Vertex's first two marketed drugs, the HIV protease inhibitors Agenerase® and Lexiva®, as well as the anti-inflammatory compounds Pralnacasan® and VX-765. In addition, he is a co-inventor on more than 30 issued patents and has authored or co-authored more than 75 scientific articles.
About Ensemble Discovery